1. 250 SEA-TGT is a nonfucosylated antibody with distinct and amplified effector function activity that leverages the dependencies of anti-TIGIT anti-tumor activity upon Fc? R engagement. (9th November 2020) Authors: Smith, Alyson; Zeng, Weiping; Siegall, William; Grogan, Bryan; Haass, Jane; Blackmarr, Amber; Thurman, Robert; Peterson, Scott; Gardai, Shyra Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 618 Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications. (9th November 2020) Authors: Klussman, Kerry; Tenn, Elena-Marie; Higgins, Shaylin; Mazahreh, Rebecca; Snead, Katie; Hamilton, Joseph; Grogan, Bryan; Sigurjonsson, Johann; Cao, Anthony; Gardai, Shyra; Liu, Bernard Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A372 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 618 Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications. (9th November 2020) Authors: Klussman, Kerry; Tenn, Elena-Marie; Higgins, Shaylin; Mazahreh, Rebecca; Snead, Katie; Hamilton, Joseph; Grogan, Bryan; Sigurjonsson, Johann; Cao, Anthony; Gardai, Shyra; Liu, Bernard Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A654 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 696 Brentuximab vedotin, a CD30-directed antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo. (10th December 2020) Authors: Grogan, Bryan; James, Reice; Ulrich, Michelle; Gardai, Shyra; Heiser, Ryan; James, Reice Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A418 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 696 Brentuximab vedotin, a CD30-directed antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo. (9th November 2020) Authors: Grogan, Bryan; James, Reice; Ulrich, Michelle; Gardai, Shyra; Heiser, Ryan; James, Reice Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A738 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗